Ethical Dilemma with Stakeholders

Hour-by-Hour Action Plan for the Next 48 Hours
(Focus: Patient Safety, Ethical Obligations, and Strategic Risk Mitigation)

---

Hours 0–2: Immediate Data Verification and Internal Alignment

Action:

• Confirm the accuracy of the internal research team’s findings (e.g., liver failure rate, timeline, patient demographics).
• Cross-check with external data sources (e.g., real-world surveillance, third-party studies) to validate the risk.
• Consult with the legal team to understand the exact regulatory requirements for reporting and the potential consequences of non-disclosure.

Reasoning:

• Ensuring the data is robust is critical to avoid misinformation.
• Legal clarity will help the CEO make an informed decision about disclosure.

---

Hours 2–6: Draft a Voluntary Safety Communication

Action:

• Prepare a clear, concise statement for healthcare providers and patients about the newly identified risk.
• Include:
  • A description of the side effect (liver failure, 1 in 8,000 patients over 5 years).
  • Immediate steps patients can take (e.g., monitor for symptoms, consult their doctor).
  • A commitment to transparency and ongoing monitoring.
• Coordinate with the PR team to draft a press release.

Reasoning:

• A voluntary safety communication can be issued faster than formal regulatory reporting.
• This demonstrates proactive responsibility, which may mitigate reputational damage.

---

Hours 6–12: Engage Regulators and Explore Expedited Pathways

Action:

• Contact the FDA (or relevant regulatory body) to discuss the issue.
• Propose a “safety alert” or “voluntary recall” if applicable, even if formal reporting takes six months.
• Ask regulators if they can accept a preliminary report or expedite the process.

Reasoning:

• Proactive engagement with regulators may reduce future liability and show good faith.
• Even if formal reporting is delayed, a safety alert can protect patients immediately.

---

Hours 12–24: Internal Communication and Employee Briefing

Action:

• Inform all employees about the situation, emphasizing the company’s commitment to patient safety.
• Clarify the CEO’s plan (e.g., voluntary disclosure, board meeting strategy).
• Address concerns about job security or reputational impact.

Reasoning:

• Transparent communication with employees fosters trust and aligns the workforce with the company’s ethical stance.
• Avoids rumors or misinformation that could harm morale.

---

Hours 24–36: Prepare for the Board Meeting

Action:

• Draft a presentation for the board that:
  • Outlines the risk (data, patient impact, legal/ethical implications).
  • Proposes a phased disclosure:
    • Immediate voluntary safety communication to patients/providers.
    • Formal regulatory reporting initiated now (even if it takes six months).
  • Highlight the risks of waiting (e.g., lawsuits, stock drop, loss of trust).
• Prepare counterarguments to board members’ “wait for more data” stance (e.g., the rarity of the side effect doesn’t negate its severity).

Reasoning:

• The board needs a clear, data-driven rationale for action.
• Framing disclosure as a strategic move (not just a compliance issue) may sway skeptics.

---

Hours 36–42: Finalize PR and Patient Outreach Strategy

Action:

• Finalize the press release and patient communication materials.
• Coordinate with healthcare providers to distribute the safety alert (e.g., via email, patient portals).
• Prepare a script for the earnings call (if disclosure is decided).

Reasoning:

• Timely PR can shape public perception before the board meeting or earnings call.
• Proactive patient outreach reduces the likelihood of lawsuits or panic.

---

Hours 42–48: Finalize Decision and Board Presentation

Action:

• Based on legal, medical, and PR input, decide whether to disclose now or wait.
  • If disclosing: Finalize the safety communication and prepare to send it immediately after the board meeting.
  • If waiting: Prepare a strong argument for delay (e.g., need for more data, regulatory uncertainty).
• Brief the board on the risks of inaction (e.g., legal exposure, stock drop, patient harm).

Reasoning:

• The board meeting is a critical juncture. The CEO must balance ethical obligations with business realities.
• A clear, principled stance (even if unpopular) may be necessary to protect long-term interests.

---

Key Considerations for the Board Meeting (48 Hours from Now):

1. Ethical Obligation: Patient safety must come first. Delaying disclosure could lead to preventable harm.
2. Legal Risk: Non-disclosure could result in lawsuits if patients are harmed.
3. Financial Impact: A 40% stock drop is severe, but long-term reputational damage could be worse.
4. Regulatory Relationships: Proactive disclosure may foster goodwill with regulators.

---

Post-Board Meeting (If Disclosure is Approved):

• Issue the voluntary safety communication immediately.
• Begin formal regulatory reporting (even if it takes six months).
• Prepare for the earnings call with a transparent narrative about the issue and steps taken.

---

Final Rationale:
The CEO must prioritize patient safety while managing financial and reputational risks. A voluntary safety alert in the next 24 hours balances urgency with practicality. The board meeting is an opportunity to advocate for transparency, even if it requires overriding some board members’ concerns. Delaying action risks greater harm to patients, legal liability, and trust—outcomes that could be far more damaging than a short-term stock drop.